Skip to main content

COVID-19 Therapeutic Monoclonal Antibody

COVID-19 Therapeutic Monoclonal Antibody

AU Health is now offering infusions for high-risk patients recently diagnosed with COVID-19.

1120 15th Street
Augusta, Georgia 30912
706-721-9449
Refer a Patient

  • COVID-19 Therapeutic Monoclonal Antibody

COVID-19 Therapeutic Monoclonal Antibody must be administered within 10 days of symptom onset (preferably <5 days) and as soon as possible after a positive viral test for SARS-CoV-2.

COVID-19 Therapeutic Monoclonal Antibody must be administered within 10 days of symptom onset (preferably <5 days) and as soon as possible after a positive viral test for SARS-CoV-2.

Patient must have a positive COVID-19 test.

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to permit the emergency use of COVID-19 Therapeutic Monoclonal Antibodies, for the treatment of mild to moderate COVID-19 in certain patients who are at high risk for progressing to severe COVID-19 and/or hospitalization. 

The following medical conditions or other factors may place adults and pediatric patients (age 12-17 years and weighing at least 40 kg) at higher risk for progressing to severe COVID-19:

  • Older age (for example age ≥65 years of age)
  • Obesity or being overweight (for example, adults with BMI >25 kg/m2, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts
  • Pregnancy
  • Chronic kidney disease
  • Diabetes
  • Immunosuppressive disease or immunosuppressive treatment
  • Cardiovascular disease (including congenital heart disease) or hypertension
  • Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
  • Sickle cell disease
  • Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
  • Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19))

Other medical conditions or factors (for example, race or ethnicity) may also place individual patients at high risk for progressing to severe COVID-19 and authorization of COVID-19 Therapeutic Monoclonal Antibodies under the EUA is not limited to the medical conditions or factors listed above. For additional information on medical conditions and factors associated with increased risk for progressing to severe COVID-19, see the CDC website. Healthcare providers should consider the benefit-risk for an individual patient.

LIMITATIONS OF AUTHORIZED USE- COVID-19 Therapeutic Monoclonal Antibodies is not authorized for use in patients:

  • who are hospitalized due to COVID-19, OR
  • who require oxygen therapy due to COVID-19, OR
  • who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Benefit of treatment with COVID-19 Therapeutic Monoclonal Antibodies has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

  • Patient must meet the inclusion criteria
  • Patient must have the following information readily available
    • Patient Name
    • DOB
    • Patient Mobile # (to initiate Virtual Care visit)
    • Patient Email
    • Date of + COVID-19 Result
    • Date of Symptom Onset
  • Patient will be screened via AU Health Virtual Care platform to verify infusion appropriateness, discuss the risks/benefits of the infusion and provide next steps
  • A health care provider can make also make a referral by calling 706-721-9449.

Provider Referral Form

Detailed instructions for infusion treatment will be provided upon scheduling.

Benefit of treatment has not been observed in patients hospitalized due to COVID-19. Monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation

Resources & Tools.

Close
Close

Personalize your experience.

Select your preferences below, so we can deliver the most relevant content to you:

Close

Personalize your experience.

Select your preferences below, so we can deliver the most relevant content to you: